BACKGROUND/AIM: We aimed to evaluate safety and efficacy of granulocyte-colony stimulating factor treatment in patients with acute on chronic liver failure and the effect of granulocyte-colony stimulating factor on the expression level of CXCR4, vascular endothelial growth factor receptor and very late activation antigen 4. METHODS: Twenty-four patients with acute on chronic liver failure were randomised to receive standard therapy, standard therapy+granulocyte-colony stimulating factor (5 microg/kg/day for 6 days) and standard therapy+granulocyte-colony stimulating factor (15 microg/kg/day s.c. for 6 days). Data on CD34+cell mobilisation were compared to age-matched peripheral blood haematopoietic stem cell donors treated with granulocyte-colony stimulating factor. On day third of treatment, the expression level of CXCR4, vascular endothelial growth factor receptor and very late activation antigen 4 was analysed in mobilised CD34+ cells. RESULTS: CD34 cell count increased after the second day of granulocyte-colony stimulating factor injection in both treatment groups compared to the linear increase observed in control. After the fifth day the increase was significantly higher in healthy donors versus patients with acute on chronic liver failure. A decrease in the expression of CXCR4, very late activation antigen 4 and vascular endothelial growth factor receptor compared to premobilisation values was observed. No major side effects were observed. CONCLUSIONS: Granulocyte-colony stimulating factor treatment is able to induce CD34 mobilisation in patients with acute on chronic liver failure. The expression pattern of CXCR4, very late activation antigen 4 and vascular endothelial growth factor receptor suggests that these molecules are involved in the granulocyte-colony stimulating factor-induced stem cell mobilisation.

Di Campli, C., Zocco, M. A., Saulnier, N., Grieco, A., Rapaccini, G. L., Addolorato, G., Rumi, C., Santoliquido, A., Leone, G., Gasbarrini, G. B., Gasbarrini, A., Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure, <<DIGESTIVE AND LIVER DISEASE>>, 2007; (39(12)): 1071-1076 [http://hdl.handle.net/10807/21985]

Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure

Di Campli, Cristiana;Zocco, Maria Assunta;Saulnier, Nathalie;Grieco, Antonio;Rapaccini, Gian Ludovico;Addolorato, Giovanni;Rumi, Carlo;Santoliquido, Angelo;Leone, Giuseppe;Gasbarrini, Giovanni Battista;Gasbarrini, Antonio
2007

Abstract

BACKGROUND/AIM: We aimed to evaluate safety and efficacy of granulocyte-colony stimulating factor treatment in patients with acute on chronic liver failure and the effect of granulocyte-colony stimulating factor on the expression level of CXCR4, vascular endothelial growth factor receptor and very late activation antigen 4. METHODS: Twenty-four patients with acute on chronic liver failure were randomised to receive standard therapy, standard therapy+granulocyte-colony stimulating factor (5 microg/kg/day for 6 days) and standard therapy+granulocyte-colony stimulating factor (15 microg/kg/day s.c. for 6 days). Data on CD34+cell mobilisation were compared to age-matched peripheral blood haematopoietic stem cell donors treated with granulocyte-colony stimulating factor. On day third of treatment, the expression level of CXCR4, vascular endothelial growth factor receptor and very late activation antigen 4 was analysed in mobilised CD34+ cells. RESULTS: CD34 cell count increased after the second day of granulocyte-colony stimulating factor injection in both treatment groups compared to the linear increase observed in control. After the fifth day the increase was significantly higher in healthy donors versus patients with acute on chronic liver failure. A decrease in the expression of CXCR4, very late activation antigen 4 and vascular endothelial growth factor receptor compared to premobilisation values was observed. No major side effects were observed. CONCLUSIONS: Granulocyte-colony stimulating factor treatment is able to induce CD34 mobilisation in patients with acute on chronic liver failure. The expression pattern of CXCR4, very late activation antigen 4 and vascular endothelial growth factor receptor suggests that these molecules are involved in the granulocyte-colony stimulating factor-induced stem cell mobilisation.
Inglese
Di Campli, C., Zocco, M. A., Saulnier, N., Grieco, A., Rapaccini, G. L., Addolorato, G., Rumi, C., Santoliquido, A., Leone, G., Gasbarrini, G. B., Gasbarrini, A., Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure, <<DIGESTIVE AND LIVER DISEASE>>, 2007; (39(12)): 1071-1076 [http://hdl.handle.net/10807/21985]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/21985
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact